Brigatinib: First Global Approval

2017/06/08 by Anthony Markham · 26 citations
Medicine · #Lung Cancer Treatments and Mutations #Gastric Cancer Management and Outcomes #Colorectal Cancer Treatments and Studies

paper · doi:10.1007/s40265-017-0776-3

Cited by

• Harnessing Oxetane and Azetidine Sulfonyl Fluorides for Opportunities in Drug Discovery
• ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. [europepmc]
• Role and targeting of anaplastic lymphoma kinase in cancer. [europepmc]
• Treating ALK-positive non-small cell lung cancer. [europepmc]
• Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. [europepmc]
• Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer. [europepmc]
• Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy. [europepmc]
• Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. [europepmc]
• Discovering Anti-Cancer Drugs via Computational Methods. [europepmc]
• A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. [europepmc]
• Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. [europepmc]
• Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. [europepmc]
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. [europepmc]
• Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. [europepmc]
• Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. [europepmc]
• FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. [europepmc]
• Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. [europepmc]
• Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. [europepmc]
• Non-small cell lung cancer in China. [europepmc]
• Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. [europepmc]
• Epigenetic regulation in lung cancer. [europepmc]
• Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. [europepmc]
• Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors? [europepmc]
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. [europepmc]
• EGFR-Targeted Therapies: A Literature Review. [europepmc]
• Harnessing Oxetane and Azetidine Sulfonyl Fluorides for Opportunities in Drug Discovery. [europepmc]